Progress towards a clinically-successful ATR inhibitor for cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Progress towards a clinically-successful ATR inhibitor for cancer therapy

Published:2021 Issue: Volume:2 Page:100017
ISSN:2590-2571
Container-title:Current Research in Pharmacology and Drug Discovery
language:en
Short-container-title:Current Research in Pharmacology and Drug Discovery

Author:

Barnieh Francis M.,Loadman Paul M.^ORCID,Falconer Robert A.^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference163 articles.

1. Cell cycle checkpoint signaling through the ATM and ATR kinases;Abraham;Genes Dev.,2001

2. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy;Al-Subhi;Breast Canc. Res. Treat.,2018

3. Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway;Alderton;Hum. Mol. Genet.,2004

4. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer;Alsubhi;Mol. Oncol.,2016

5. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles;Arris;J. Med. Chem.,2000

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. Recent advancement of analytical approaches for assessing Ataxia telangiectasia mutated kinase inhibitors in Ataxia telangiectasia: An overview;Process Biochemistry;2024-09

3. Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators;Molecular & Cellular Proteomics;2024-08

4. Hypoxia‐Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment‐Resistant Cancer Cells;Advanced Science;2024-07-08

5. Discovery of UMI-77 as a novel Ku70/80 inhibitor sensitizing cancer cells to DNA damaging agents in vitro and in vivo;European Journal of Pharmacology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3